KFDA approved clinical studies for Sewon Cellontech's Ostem.

Published: 2006-01-03 07:00:00

Updated: 2006-01-03 07:00:00

Sewon Cellontech announced on Dec. 28 that the KFDA approved the clinical study for Ostem, a cell therapy by differentiating adult stem cells into osteoblasts to treat bone necrotic disease.

The clinical study may be led by Prof. Kim Jeong-man, an orthopedic surgeon of Kangnam St. Mary hospita...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK